Primary source: Open Government Licence v3.0
The Youth Justice Board publicly stated its opposition to the extended use of PAVA in youth custody, characterizing this extension as a step in the wrong direction and advocating for reforms toward smaller, professional units for youth management.
This response could reshape compliance practices concerning the use of PAVA in youth institutions, influencing future regulations and treatment standards in youth justice.
Monitor compliance practices regarding PAVA use in youth custody settings and assess alignment with the YJB's concerns and evidential claims on efficacy and safety.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Monitor compliance practices regarding PAVA use in youth custody settings and assess alignment with the YJB's concerns and evidential claims on efficacy and safety.
The Youth Justice Board (YJB) has formally opposed the extension of the PAVA (synthetic pepper spray) rollout at Young Offender Institutions, highlighting concerns about its lack of efficacy in reducing violence and the potential for significant harm, particularly to vulnerable groups.
What changed: The Youth Justice Board publicly stated its opposition to the extended use of PAVA in youth custody, characterizing this extension as a step in the wrong direction and advocating for reforms toward smaller, professional units for youth management.
Why it matters: This response could reshape compliance practices concerning the use of PAVA in youth institutions, influencing future regulations and treatment standards in youth justice.
Practical implication: Monitor compliance practices regarding PAVA use in youth custody settings and assess alignment with the YJB's concerns and evidential claims on efficacy and safety.
Published from the regulator source ingestion pipeline after PV impact triage.
Regulatory intelligence should be updated to reflect the new PSUSA, and signal management processes may require reviews based on new safety information.
Update product labels to include prevention indications for Capstar and Nitenpyram Tablets. Ensure that labeling reflects new usage guidelines for these products as outlined in the Emergency Use Authorization.
Review compliance with PREA obligations, prepare responses to any received non-compliance letters, and ensure any necessary deferral extension requests are properly submitted within the specified timeframe.
Healthcare establishments must quarantine the affected Eyefill C lots, refrain from using them, and monitor patients who received the device.
